皮膚糸状菌性爪真菌症治療薬（DOT）の世界市場（～2026年）

• 英文タイトル：Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY11621 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は皮膚糸状菌性爪真菌症治療薬（DOT）のグローバル市場について調査・分析したレポートです。種類別（局所、経口療法）市場規模、用途別（病院、皮膚科・足病医院、独立薬局、通信販売薬局、ドラッグストア）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別皮膚糸状菌性爪真菌症治療薬（DOT）の競争状況、市場シェア ・世界の皮膚糸状菌性爪真菌症治療薬（DOT）市場：種類別市場規模 2015年-2020年（局所、経口療法） ・世界の皮膚糸状菌性爪真菌症治療薬（DOT）市場：種類別市場規模予測 2021年-2026年（局所、経口療法） ・世界の皮膚糸状菌性爪真菌症治療薬（DOT）市場：用途別市場規模 2015年-2020年（病院、皮膚科・足病医院、独立薬局、通信販売薬局、ドラッグストア） ・世界の皮膚糸状菌性爪真菌症治療薬（DOT）市場：用途別市場規模予測 2021年-2026年（病院、皮膚科・足病医院、独立薬局、通信販売薬局、ドラッグストア） ・北米の皮膚糸状菌性爪真菌症治療薬（DOT）市場分析：米国、カナダ ・ヨーロッパの皮膚糸状菌性爪真菌症治療薬（DOT）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの皮膚糸状菌性爪真菌症治療薬（DOT）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の皮膚糸状菌性爪真菌症治療薬（DOT）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの皮膚糸状菌性爪真菌症治療薬（DOT）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Galderma、Bausch Health、Novartis、Pfizer、Janssen ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market growth is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Easy application of nail paints is also expected to drive demand for dermatophytic onychomycosis drugs. However, adverse effects associated with anti-fungal drugs and lack of awareness about dermatophytic onychomycosis in Asia Pacific, Middle East and Africa, and Latin America are expected to impede growth of the global dermatophytic onychomycosis therapeutics market.
The global dermatophytic onychomycosis therapeutics market is anticipated to expand at a healthy CAGR during the forecast period. By product type, the market is segmented into Nail paint and tablet, which is again sub-divided into prescription (Rx) and over-the-counter (OTC) sub segments. The nail paint segment is expected to contribute a maximum share to the global dermatophytic onychomycosis therapeutics market. By treatment, the market is segmented into topical and oral therapy. Among these, the topical segment is anticipated to be dominant throughout the forecast period and projected to account for about 70% share of the total global dermatophytic onychomycosis market revenue by 2025.

Market Analysis and Insights: Global Dermatophytic Onychomycosis Therapeutics (DOT) Market
The global Dermatophytic Onychomycosis Therapeutics (DOT) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Dermatophytic Onychomycosis Therapeutics (DOT) Scope and Market Size
Dermatophytic Onychomycosis Therapeutics (DOT) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Dermatophytic Onychomycosis Therapeutics (DOT) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Galderma
Bausch Health
Novartis
Pfizer
Janssen
…

Market segment by Type, the product can be split into
Topical
Oral Therapy
Market segment by Application, split into
Hospitals
Dermatology And Podiatry Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Dermatophytic Onychomycosis Therapeutics (DOT) Revenue
1.4 Market by Type
1.4.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Topical
1.4.3 Oral Therapy
1.5 Market by Application
1.5.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Dermatology And Podiatry Clinics
1.5.4 Independent Pharmacies
1.5.5 Mail Order Pharmacies
1.5.6 Drug Stores
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Perspective (2015-2026)
2.2 Global Dermatophytic Onychomycosis Therapeutics (DOT) Growth Trends by Regions
2.2.1 Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Dermatophytic Onychomycosis Therapeutics (DOT) Historic Market Share by Regions (2015-2020)
2.2.3 Dermatophytic Onychomycosis Therapeutics (DOT) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Dermatophytic Onychomycosis Therapeutics (DOT) Market Growth Strategy
2.3.6 Primary Interviews with Key Dermatophytic Onychomycosis Therapeutics (DOT) Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Dermatophytic Onychomycosis Therapeutics (DOT) Players by Market Size
3.1.1 Global Top Dermatophytic Onychomycosis Therapeutics (DOT) Players by Revenue (2015-2020)
3.1.2 Global Dermatophytic Onychomycosis Therapeutics (DOT) Revenue Market Share by Players (2015-2020)
3.1.3 Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Concentration Ratio
3.2.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Dermatophytic Onychomycosis Therapeutics (DOT) Revenue in 2019
3.3 Dermatophytic Onychomycosis Therapeutics (DOT) Key Players Head office and Area Served
3.4 Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Product Solution and Service
3.5 Date of Enter into Dermatophytic Onychomycosis Therapeutics (DOT) Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Historic Market Size by Type (2015-2020)
4.2 Global Dermatophytic Onychomycosis Therapeutics (DOT) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020)
5.2 Global Dermatophytic Onychomycosis Therapeutics (DOT) Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size (2015-2020)
6.2 Dermatophytic Onychomycosis Therapeutics (DOT) Key Players in North America (2019-2020)
6.3 North America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020)
6.4 North America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020)

7 Europe
7.1 Europe Dermatophytic Onychomycosis Therapeutics (DOT) Market Size (2015-2020)
7.2 Dermatophytic Onychomycosis Therapeutics (DOT) Key Players in Europe (2019-2020)
7.3 Europe Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020)
7.4 Europe Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020)

8 China
8.1 China Dermatophytic Onychomycosis Therapeutics (DOT) Market Size (2015-2020)
8.2 Dermatophytic Onychomycosis Therapeutics (DOT) Key Players in China (2019-2020)
8.3 China Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020)
8.4 China Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020)

9 Japan
9.1 Japan Dermatophytic Onychomycosis Therapeutics (DOT) Market Size (2015-2020)
9.2 Dermatophytic Onychomycosis Therapeutics (DOT) Key Players in Japan (2019-2020)
9.3 Japan Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020)
9.4 Japan Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Dermatophytic Onychomycosis Therapeutics (DOT) Market Size (2015-2020)
10.2 Dermatophytic Onychomycosis Therapeutics (DOT) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020)
10.4 Southeast Asia Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020)

11 India
11.1 India Dermatophytic Onychomycosis Therapeutics (DOT) Market Size (2015-2020)
11.2 Dermatophytic Onychomycosis Therapeutics (DOT) Key Players in India (2019-2020)
11.3 India Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020)
11.4 India Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size (2015-2020)
12.2 Dermatophytic Onychomycosis Therapeutics (DOT) Key Players in Central & South America (2019-2020)
12.3 Central & South America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020)
12.4 Central & South America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Galderma
13.1.1 Galderma Company Details
13.1.2 Galderma Business Overview
13.1.3 Galderma Dermatophytic Onychomycosis Therapeutics (DOT) Introduction
13.1.4 Galderma Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) Business (2015-2020))
13.1.5 Galderma Recent Development
13.2 Bausch Health
13.2.1 Bausch Health Company Details
13.2.2 Bausch Health Business Overview
13.2.3 Bausch Health Dermatophytic Onychomycosis Therapeutics (DOT) Introduction
13.2.4 Bausch Health Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) Business (2015-2020)
13.2.5 Bausch Health Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview
13.3.3 Novartis Dermatophytic Onychomycosis Therapeutics (DOT) Introduction
13.3.4 Novartis Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer Dermatophytic Onychomycosis Therapeutics (DOT) Introduction
13.4.4 Pfizer Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Janssen
13.5.1 Janssen Company Details
13.5.2 Janssen Business Overview
13.5.3 Janssen Dermatophytic Onychomycosis Therapeutics (DOT) Introduction
13.5.4 Janssen Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) Business (2015-2020)
13.5.5 Janssen Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Dermatophytic Onychomycosis Therapeutics (DOT) Key Market Segments
Table 2. Key Players Covered: Ranking by Dermatophytic Onychomycosis Therapeutics (DOT) Revenue
Table 3. Ranking of Global Top Dermatophytic Onychomycosis Therapeutics (DOT) Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Topical
Table 6. Key Players of Oral Therapy
Table 7. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Regions (2015-2020)
Table 11. Global Dermatophytic Onychomycosis Therapeutics (DOT) Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Dermatophytic Onychomycosis Therapeutics (DOT) Market Growth Strategy
Table 17. Main Points Interviewed from Key Dermatophytic Onychomycosis Therapeutics (DOT) Players
Table 18. Global Dermatophytic Onychomycosis Therapeutics (DOT) Revenue by Players (2015-2020) (Million US$)
Table 19. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Players (2015-2020)
Table 20. Global Top Dermatophytic Onychomycosis Therapeutics (DOT) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) as of 2019)
Table 21. Global Dermatophytic Onychomycosis Therapeutics (DOT) by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Product Solution and Service
Table 24. Date of Enter into Dermatophytic Onychomycosis Therapeutics (DOT) Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020) (Million US$)
Table 27. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size Share by Type (2015-2020)
Table 28. Global Dermatophytic Onychomycosis Therapeutics (DOT) Revenue Market Share by Type (2021-2026)
Table 29. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size Share by Application (2015-2020)
Table 30. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020) (Million US$)
Table 31. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size Share by Application (2021-2026)
Table 32. North America Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Market Share (2019-2020)
Table 34. North America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020) (Million US$)
Table 35. North America Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Type (2015-2020)
Table 36. North America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020) (Million US$)
Table 37. North America Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Application (2015-2020)
Table 38. Europe Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Market Share (2019-2020)
Table 40. Europe Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Type (2015-2020)
Table 42. Europe Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Application (2015-2020)
Table 44. China Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Revenue (2019-2020) (Million US$)
Table 45. China Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Market Share (2019-2020)
Table 46. China Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020) (Million US$)
Table 47. China Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Type (2015-2020)
Table 48. China Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020) (Million US$)
Table 49. China Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Application (2015-2020)
Table 50. Japan Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Market Share (2019-2020)
Table 52. Japan Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Type (2015-2020)
Table 54. Japan Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Market Share (2019-2020)
Table 58. Southeast Asia Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Type (2015-2020)
Table 60. Southeast Asia Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Application (2015-2020)
Table 62. India Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Revenue (2019-2020) (Million US$)
Table 63. India Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Market Share (2019-2020)
Table 64. India Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020) (Million US$)
Table 65. India Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Type (2015-2020)
Table 66. India Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020) (Million US$)
Table 67. India Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Dermatophytic Onychomycosis Therapeutics (DOT) Market Share (2019-2020)
Table 70. Central & South America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Type (2015-2020)
Table 72. Central & South America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Application (2015-2020)
Table 74. Galderma Company Details
Table 75. Galderma Business Overview
Table 76. Galderma Product
Table 77. Galderma Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) Business (2015-2020) (Million US$)
Table 78. Galderma Recent Development
Table 79. Bausch Health Company Details
Table 80. Bausch Health Business Overview
Table 81. Bausch Health Product
Table 82. Bausch Health Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) Business (2015-2020) (Million US$)
Table 83. Bausch Health Recent Development
Table 84. Novartis Company Details
Table 85. Novartis Business Overview
Table 86. Novartis Product
Table 87. Novartis Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) Business (2015-2020) (Million US$)
Table 88. Novartis Recent Development
Table 89. Pfizer Company Details
Table 90. Pfizer Business Overview
Table 91. Pfizer Product
Table 92. Pfizer Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) Business (2015-2020) (Million US$)
Table 93. Pfizer Recent Development
Table 94. Janssen Company Details
Table 95. Janssen Business Overview
Table 96. Janssen Product
Table 97. Janssen Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) Business (2015-2020) (Million US$)
Table 98. Janssen Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Type: 2020 VS 2026
Figure 2. Topical Features
Figure 3. Oral Therapy Features
Figure 4. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Dermatology And Podiatry Clinics Case Studies
Figure 7. Independent Pharmacies Case Studies
Figure 8. Mail Order Pharmacies Case Studies
Figure 9. Drug Stores Case Studies
Figure 10. Dermatophytic Onychomycosis Therapeutics (DOT) Report Years Considered
Figure 11. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Regions: 2020 VS 2026
Figure 13. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Players in 2019
Figure 16. Global Top Dermatophytic Onychomycosis Therapeutics (DOT) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dermatophytic Onychomycosis Therapeutics (DOT) as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Dermatophytic Onychomycosis Therapeutics (DOT) Revenue in 2019
Figure 18. North America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Dermatophytic Onychomycosis Therapeutics (DOT) Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Dermatophytic Onychomycosis Therapeutics (DOT) Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Dermatophytic Onychomycosis Therapeutics (DOT) Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Dermatophytic Onychomycosis Therapeutics (DOT) Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Dermatophytic Onychomycosis Therapeutics (DOT) Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Dermatophytic Onychomycosis Therapeutics (DOT) Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed

---